News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PDL BioPharma (PDLI): Now Is The Time To Buy



5/19/2017 6:08:49 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
PDL BioPharma's (NASDAQ:PDLI) shares are significantly undervalued (I believe this, and so does PDL management). Now is the time to buy. At present, PDLI has $2.45 per share of cash, a 1.74 cash to debt ratio, hidden assets about to be unlocked, and a low valuation, trading at a forward P/E of 13.75. I predict PDLI could increase 50% due to upcoming acquisitions, increasing earnings, share buybacks, and the market's realization of PDLI's current valuation. In short, the market has turned a blind eye to PDL's balance sheet and it doesn't believe in these catalysts propositions because the company had a disappointing 2016.

Read at Seeking Alpha


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES